FTC v. Golden Sunrise Nutraceutical, Inc., et al.
LAST UPDATED: JULY 31, 2020
CASE STATUS: Pending
Federal Trade Commission, Plaintiff, v. Golden Sunrise Nutraceutical, Inc., a corporation; Golden Sunrise Pharmaceutical, Inc., a corporation; Huu Tieu, individually and as an officer of Golden Sunrise Nutraceutical, Inc. and Golden Sunrise Pharmaceutical, Inc.; and Stephen Meis, individually and as an officer of Golden Sunrise Nutraceutical, Inc.; Defendants.
FTC MATTER/FILE NUMBER: 202 3146
CIVIL ACTION NUMBER: 1:20-at-00540
ENFORCEMENT TYPE: Federal Injunctions
FEDERAL COURT: Eastern District of California
CASE SUMMARY
In July 2020, the Federal Trade Commission filed a complaint in federal court against the California-based marketers and promoters of bogus treatments for serious medical conditions. The defendants are two corporations headquartered in Porterville, California, and two of their executives: Huu Tieu, President and CEO of both companies; and Stephen Weis, Medical Director and board member of Golden Sunrise Nutraceutical. The complaint alleges that defendants have promoted and sold a variety of products through "plans of care" ranging in price from $23,000 to $200,000, which falsely claim to treat or cure COVID-19, cancer, Parkinson's disease, etc.
CASE TIMELINE
July 31, 2020
Complaint for Permanent Injunction and Other Equitable Relief (539.87 KB)
PRESS RELEASE: FTC Sues California Marketer of $23,000 COVID-19 “Treatment” Plan
For more information, see here: https://www.ftc.gov/enforcement/cases-proceedings/202-3146/golden-sunrise-nutraceutical-inc
These materials were obtained directly from the Federal Government public websites and are posted here for your review and reference only. No Claim to Original U.S. Government Works. These may not be the most recent versions. The U.S. Government may have more current information. We make no guarantees or warranties about the accuracy or completeness of this information or the information linked to. Please check the linked sources directly.
